Agenus Inc. (NASDAQ:AGEN – Free Report) – Stock analysts at HC Wainwright decreased their Q3 2026 earnings per share (EPS) estimates for shares of Agenus in a report released on Monday, July 13th. HC Wainwright analyst E. Bodnar now anticipates that the biotechnology company will post earnings of $0.03 per share for the quarter, down from their previous estimate of $0.05. HC Wainwright currently has a “Buy” rating and a $30.00 target price on the stock. The consensus estimate for Agenus’ current full-year earnings is $0.02 per share. HC Wainwright also issued estimates for Agenus’ Q4 2026 earnings at $0.01 EPS.
Several other equities analysts have also weighed in on AGEN. Weiss Ratings restated a “sell (d)” rating on shares of Agenus in a research note on Tuesday, June 16th. Wall Street Zen upgraded shares of Agenus from a “hold” rating to a “buy” rating in a research report on Monday, April 6th. Finally, Zacks Research downgraded shares of Agenus from a “strong-buy” rating to a “hold” rating in a research report on Monday, May 11th. One analyst has rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, Agenus presently has an average rating of “Hold” and a consensus target price of $30.00.
Agenus Trading Up 83.6%
NASDAQ AGEN opened at $6.15 on Tuesday. The company has a fifty day simple moving average of $3.35 and a two-hundred day simple moving average of $3.44. Agenus has a 12-month low of $2.71 and a 12-month high of $8.70. The stock has a market cap of $256.09 million, a P/E ratio of 3.87 and a beta of 1.55.
Agenus (NASDAQ:AGEN – Get Free Report) last released its earnings results on Monday, May 11th. The biotechnology company reported $1.02 earnings per share for the quarter, missing analysts’ consensus estimates of $2.10 by ($1.08). Agenus had a negative return on equity of 31.66% and a net margin of 50.49%.The business had revenue of $33.74 million during the quarter, compared to analysts’ expectations of $129.50 million.
Institutional Inflows and Outflows
Several institutional investors and hedge funds have recently bought and sold shares of AGEN. LPL Financial LLC increased its stake in Agenus by 20.3% in the fourth quarter. LPL Financial LLC now owns 23,326 shares of the biotechnology company’s stock valued at $73,000 after purchasing an additional 3,943 shares during the period. EP Wealth Advisors LLC acquired a new position in Agenus during the fourth quarter worth about $31,000. Jump Financial LLC acquired a new stake in shares of Agenus in the 2nd quarter worth approximately $55,000. R Squared Ltd purchased a new position in Agenus in the 4th quarter valued at approximately $41,000. Finally, Squarepoint Ops LLC acquired a new position in Agenus during the third quarter worth $54,000. 61.46% of the stock is owned by institutional investors and hedge funds.
Key Headlines Impacting Agenus
Here are the key news stories impacting Agenus this week:
- Positive Sentiment: Agenus announced an oversubscribed private placement for about $85 million upfront, with up to $255 million more available through warrants, giving it substantially more capital to fund development. Article Title
- Positive Sentiment: The company is narrowing its strategy around the ROBBIN Phase 3 trial of BOT+BAL in microsatellite-stable colon cancer, which investors view as a clearer path to potential value creation. Article Title
- Positive Sentiment: HC Wainwright maintained a Buy rating and raised its price target to $30, reinforcing bullish sentiment despite trimming near-term earnings estimates. Article Title
- Neutral Sentiment: HC Wainwright lowered its Q3 2026 EPS estimate to $0.03 from $0.05 and Q4 2026 EPS estimate to $0.01 from $0.04, reflecting more conservative near-term expectations. Article Title
- Negative Sentiment: Agenus is discontinuing financial support for its BATTMAN metastatic colorectal cancer study, which may be seen as a setback for that program even as it reallocates resources to its lead trial. Article Title
Agenus Company Profile
Agenus, Inc (NASDAQ:AGEN) is a clinical-stage immuno-oncology company headquartered in Lexington, Massachusetts. The company focuses on the discovery and development of therapies designed to modulate the immune system’s response to cancer. Leveraging proprietary platforms in checkpoint modulation, vaccine technology and adjuvant systems, Agenus aims to deliver combination regimens that enhance antitumor activity across a variety of solid tumors and hematological malignancies.
Agenus’ pipeline includes monoclonal antibodies targeting immune checkpoints, cytokine-based therapeutics and vaccine candidates built on its engineered heat shock protein (HSP) platform.
Featured Articles
- Five stocks we like better than Agenus
- The SK Hynix IPO and 2027’s AI Memory Squeeze
- Meta Platforms Stock Rises as Muse Spark 1.1 AI Model Debuts
- Why Welltower’s Growth Story Might Outrun Its Rich Valuation
- One Short- and One Long-Term ETF for Quantum Computing Bulls
Receive News & Ratings for Agenus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agenus and related companies with MarketBeat.com's FREE daily email newsletter.
